You are here: Industry Insights > GSK

News List

GSK and Alector announce global collaboration in immuno-neurology worldpharmanews
July 05, 2021
GlaxoSmithKline plc and Alector, announced a strategic global collaboration for the development and commercialisation of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels.
GSK Singapore and Vir Biotechnology Announce Advance Purchase Agreement with the Government of Singapore for Monoclonal Antibody Sotrovimab (VIR-7831) prnasia
June 30, 2021
GlaxoSmithKline Singapore and Vir Biotechnology announced an agreement with the Government of Singapore for the supply of sotrovimab, an investigational single-dose monoclonal antibody, for the treatment of patients with COVID-19 who do not require ...
GSK to boost growth with Consumer Healthcare business spin-off pharmaceutical-technology
June 25, 2021
GlaxoSmithKline (GSK) has plans to spin off its consumer healthcare unit into a separate company while the resultant New GSK will focus on developing vaccines and speciality drugs.
GSK, Vir say final data confirm efficacy of recently authorised COVID-19 antibody sotrovimab firstwordpharma
June 22, 2021
GlaxoSmithKline and Vir Biotechnology on Monday reported final results from the Phase III COMET-ICE trial confirming that early use of sotrovimab significantly reduces hospitalisation and death in COVID-19 outpatients at high risk of worsening to severe
iTeos Therapeutics, GSK Enter Monoclonal Antibody Alliance contractpharma
June 15, 2021
GSK now has a leading portfolio of antibodies targeting the CD226 axis, a key target for next-gen immuno-oncology therapies.
GSK’s PD-1 inhibitor Jemperli approved in the UK pharmatimes
June 08, 2021
GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of recurrent or advanced endometrial cancer.
NICE turns down GSK's IV Benlysta for systemic lupus pharmatimes
June 04, 2021
The National Institute for Health and Care Excellence (NICE) has rejected NHS funding for an intravenous formulation of GlaxoSmithKline's Benlysta (belimumab) as an add-on therapy for certain patients with active autoantibody-positive systemic lupus.
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate worldpharmanews
May 28, 2021
Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate.
GSK, Sanofi launch late-stage COVID-19 vaccine study pharmatimes
May 27, 2021
GlaxoSmithKline (GSK) and Sanofi have begun enrolling participants into a Phase III clinical study of their adjuvanted recombinant-protein COVID-19 vaccine candidate.
GSK-Vir’s Covid-19 drug sotrovimab obtains positive EMA opinion pharmaceutical-technology
May 25, 2021
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has issued a positive scientific opinion for GlaxoSmithKline (GSK) and Vir Biotechnology’s sotrovimab (VIR-7831) as early Covid-19 treatment.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page